# EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML

> **NCT02533115** · — · APPROVED_FOR_MARKETING · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Secondary AML

## Interventions

- **DRUG:** CPX-351

## Key facts

- **NCT ID:** NCT02533115
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533115, "EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02533115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*